EMA Withdrawn: Rilonacept Regeneron (previously Arcalyst) (rilonacept) — Regeneron UK Limited

View source ↗

Summary

The EMA has withdrawn the marketing authorization for rilonacept (Regeneron UK Limited) previously branded Arcalyst, for Cryopyrin-Associated Periodic Syndromes…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cryopyrin-associated Periodic Syndromes

Drugs mentioned

• Arcalyst (rilonacept)
• Rilonacept (rilonacept)

Snippet

Status: Withdrawn. Therapeutic area: Cryopyrin-Associated Periodic Syndromes. MAH: Regeneron UK Limited. Decision date: 28/06/2012